EGFR and colorectal cancer: The usefulness of DNA methylation assays as an aid in selecting anti-EGFR antibody drugs was described in the Japanese Society of Clinical Oncology’s “5th Edition of the Guidelines for Genetic Testing in the Diagnosis and Treatment of Colorectal Cancer” in June 2023, one year before the assay was approved for use in Japan (10).